Get my own profile
Public access
View all19 articles
5 articles
available
not available
Based on funding mandates
Co-authors
Mary-Claire KingUniversity of WashingtonVerified email at uw.edu
Mark LacknerChief Scientific Officer, ZentalisVerified email at zentalis.com
Bruce Ponderprofessor of oncology Cambridge universityVerified email at cruk.cam.ac.uk
Anneleen DaemenGenentech, IncVerified email at gene.com
Peter HavertyGinkgo BioworksVerified email at ginkgobioworks.com
Greg PlowmanVP Oncology Research, LillyVerified email at imclone.com
Bart VanhaesebroeckUCL Cancer Institute, University College London, London UKVerified email at ucl.ac.uk
Mark MerchantDirector, Department of Translational Oncology, GenentechVerified email at gene.com
Melissa R JunttilaORIC PharmaceuticalsVerified email at oricpharma.com
Thistlethwaite FThe Christie NHS Foundation Trust and University of ManchesterVerified email at nhs.net
Mark SliwkowskiDistinguished Staff Scientist (Genentech, retired). Denali TherapeuticsVerified email at dnli.com
David StokoeCalicoVerified email at calicolabs.com
Klaus OkkenhaugDivision of Immunology, Department of Pathology, University of CambridgeVerified email at cam.ac.uk
Don KirkpatrickSVP, Xaira TherapeuticsVerified email at xaira.com
Joachim RudolphGenentechVerified email at gene.com
Ciara MetcalfeScientist, Translational Oncology, GenentechVerified email at gene.com
Adrian Jubb, MD PhD23andMeVerified email at 23andme.com